Positive topline results reported in run-in cohort of reproxalap phase 3 trial

Reproxalap demonstrated statistically significant improvements in dry eye symptoms, redness and Schirmer’s test results compared with vehicle in a run-in cohort of the phase 3 TRANQUILITY clinical trial, Aldeyra Therapeutics announced.
The 23 participants in the double-masked, single-center, parallel-group run-in cohort were randomly assigned to receive either 0.25% reproxalap or vehicle ophthalmic solution, according to a press release. Doses were administered four times the day before and two times the day of a 90-minute exposure to a dry eye chamber with low humidity, high airflow and

Full Story →